Dianthus Therapeutics, Inc. /DE/

DNTH · Biotech · Nasdaq · As of 10 Sep 2026

FundamentalsNot enough data yet
ValueNot enough data yet
News flowBalanced
MomentumVery strong
SafetyStrong

Overall confidence 37/100 — few inputs available yet

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

Discovery Gap: Medium (17/100) · Gap confidence 62/100Some evidence isn't yet fully priced in.

This month at a glance

AIR Score™ change: -1Slipped -1 on softer inputs.

Cycle window9 Sep 2026 → 10 Sep 2026

Momentum-1Weighed on the latest score.

Evidence timeline

[8-K 2.02] Dianthus Therapeutics, Inc. /DE/ — Results of Operations and Financial ConditionSEC · SEC EDGAR
Aug 4, 2026 · 8-K
[8-K 8.01] Dianthus Therapeutics, Inc. /DE/ — Other EventsSEC · SEC EDGAR
Jun 12, 2026 · 8-K
[8-K 2.02] Dianthus Therapeutics, Inc. /DE/ — Results of Operations and Financial ConditionSEC · SEC EDGAR
May 5, 2026 · 8-K
[8-K 8.01] Dianthus Therapeutics, Inc. /DE/ — Other EventsSEC · SEC EDGAR
Mar 26, 2026 · 8-K
[8-K 1.01] Dianthus Therapeutics, Inc. /DE/ — Entry into a Material Definitive AgreementSEC · SEC EDGAR
Mar 10, 2026 · 8-K
[8-K 8.01] Dianthus Therapeutics, Inc. /DE/ — Other EventsSEC · SEC EDGAR
Mar 9, 2026 · 8-K
[8-K 2.02] Dianthus Therapeutics, Inc. /DE/ — Results of Operations and Financial ConditionSEC · SEC EDGAR
Mar 9, 2026 · 8-K
[8-K 2.02] Dianthus Therapeutics, Inc. /DE/ — Results of Operations and Financial ConditionSEC · SEC EDGAR
Jan 12, 2026 · 8-K
[8-K 2.02] Dianthus Therapeutics, Inc. /DE/ — Results of Operations and Financial ConditionSEC · SEC EDGAR
Nov 5, 2025 · 8-K
[8-K 8.01] Dianthus Therapeutics, Inc. /DE/ — Other EventsSEC · SEC EDGAR
Nov 3, 2025 · 8-K
[8-K 2.02] Dianthus Therapeutics, Inc. /DE/ — Results of Operations and Financial ConditionSEC · SEC EDGAR
Oct 16, 2025 · 8-K
[8-K 1.01] Dianthus Therapeutics, Inc. /DE/ — Entry into a Material Definitive AgreementSEC · SEC EDGAR
Oct 16, 2025 · 8-K

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or a new evidence cluster that re-opens a distance between filings and attention would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.